Forums
4 posts
• Page 1 of 1
Nutlin and other cousins
We had a short correspondence with researcher Prof. Croce. He leaded a study about microRNA in multiple myeloma. My question is, if myloma experts are trying to bring already existing agents (as nutlin) to the patients? Same thing with HIV proteasome inhibitors. There are many immunomodulary drugs in HIV which could possibly help in myeloma therapy. While new agents are desperately needed, as Dr. Rajkumar pointed out at Beacon's forum, my question is, if myeloma researchers have a look on this cousin drugs. Could it be a strategy to transfer proven drugs from other research fields? And do you know projects, that are successful in myeloma?
Study?
Peter, do you mean this study?
http://www.biologynews.net/archives/2010/10/26/study_identifies_key_molecules_in_multiple_myeloma.html
http://www.biologynews.net/archives/2010/10/26/study_identifies_key_molecules_in_multiple_myeloma.html
Re: Nutlin and other cousins
Hi
This is for peter parker and thomas I.
Nutlin is a molecule that is being tested as an anti-cancer agent as it increases p53 activity which is a tumor suppressor gene that encodes for a protein that is involved in cell division. It may cause this effect on p53 by interfering with MDM2 which stands for murine double minute 2 oncogene which can inhibit p53 function. MDM2 has been found in high levels in some multiple myeloma cell lines. It also appears to interact with another oncogene called ras. Of note, p53 is located on chromosome 17. It is thought that disruption of this gene by the 17p deletion in multiple myeloma is related to the high risk nature of multiple myeloma with this cytogenetic abnormality. Phase I toxicity trials are planned for patients with a variety of malignancies to see if nutlin or other MDM2 inhibitors can then be safely tested in Phase II studies to see if they will interfere with growth in cancers including multiple myeloma. Dr. Croce's work at Ohio State looked at microRNAs (mRNAs) which regulate gene expression. His lab found that activating silenced mRNAs that interfere with MDM2 in myeloma cells led to inhibition of the growth of myeloma cells. What will need to take place is screening for drugs that can increase these mRNAs or devise other strategies to increase their levels in the multiple myeloma cells. A colleague of mine named David Frank at the Dana Farber has been screening FDA-approved drugs for anti-stat activity in cancer cells. He found a drug called pyrimethamine which is an antibiotic, will inhibit stat activity in chronic lymphocytic leukemia (CLL) and he and his colleagues are testing this drug in a clinical trial for CLL patients. So here is an example of using an FDA-approved drug for another purpose. Similarly a colleague of mine at RPCI, Dr. Andrei Gudkov is testing a variety of small molecules for anti-cancer effects in the lab and then will work on bringing these molecules to the clinic.
This is for peter parker and thomas I.
Nutlin is a molecule that is being tested as an anti-cancer agent as it increases p53 activity which is a tumor suppressor gene that encodes for a protein that is involved in cell division. It may cause this effect on p53 by interfering with MDM2 which stands for murine double minute 2 oncogene which can inhibit p53 function. MDM2 has been found in high levels in some multiple myeloma cell lines. It also appears to interact with another oncogene called ras. Of note, p53 is located on chromosome 17. It is thought that disruption of this gene by the 17p deletion in multiple myeloma is related to the high risk nature of multiple myeloma with this cytogenetic abnormality. Phase I toxicity trials are planned for patients with a variety of malignancies to see if nutlin or other MDM2 inhibitors can then be safely tested in Phase II studies to see if they will interfere with growth in cancers including multiple myeloma. Dr. Croce's work at Ohio State looked at microRNAs (mRNAs) which regulate gene expression. His lab found that activating silenced mRNAs that interfere with MDM2 in myeloma cells led to inhibition of the growth of myeloma cells. What will need to take place is screening for drugs that can increase these mRNAs or devise other strategies to increase their levels in the multiple myeloma cells. A colleague of mine named David Frank at the Dana Farber has been screening FDA-approved drugs for anti-stat activity in cancer cells. He found a drug called pyrimethamine which is an antibiotic, will inhibit stat activity in chronic lymphocytic leukemia (CLL) and he and his colleagues are testing this drug in a clinical trial for CLL patients. So here is an example of using an FDA-approved drug for another purpose. Similarly a colleague of mine at RPCI, Dr. Andrei Gudkov is testing a variety of small molecules for anti-cancer effects in the lab and then will work on bringing these molecules to the clinic.
-
Dr. Philip McCarthy - Name: Philip McCarthy Jr., M.D.
Re: Nutlin and other cousins
Dear Dr. McCarthy
My father is del17 patient.
Is there any possibility to get "nutlin" for him here in germany?
Thanks,
Katrin
My father is del17 patient.
Is there any possibility to get "nutlin" for him here in germany?
Thanks,
Katrin
-
Katrin
4 posts
• Page 1 of 1
Return to Treatments & Side Effects